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Abstract
 
Multiple sclerosis is a demyelinating disorder of the central nervous system (CNS), in which an
immune attack directed against myelin constituents causes myelin destruction and death of oli-
godendrocytes, the myelin-producing cells. Here, the efficacy of nerve growth factor (NGF), a
growth factor for neurons and oligodendrocytes, in promoting myelin repair was evaluated us-
ing the demyelinating model of experimental allergic encephalomyelitis (EAE) in the common
marmoset. Surprisingly, we found that NGF delayed the onset of clinical EAE and, pathologi-
cally, prevented the full development of EAE lesions. We demonstrate by immunocytochemis-
try that NGF exerts its antiinflammatory effect by downregulating the production of interferon
 
g
 
 by T cells infiltrating the CNS, and upregulating the production of interleukin 10 by glial
cells in both inflammatory lesions of EAE and normal-appearing CNS white matter. Thus,
NGF, currently under investigation in human clinical trials as a neuronal trophic factor, may be
an attractive candidate for therapy of autoimmune demyelinating disorders.
Key words: multiple sclerosis • nonhuman primate • interferon 
 
g
 
 • interleukin 10 • growth 
factors
 
Introduction
 
Multiple sclerosis (MS) is a chronic, relapsing-remitting
disease of the central nervous system (CNS) white matter
characterized pathologically by perivenular infiltration of
mononuclear cells and macrophages, demyelination with
astrocyte proliferation and gliosis, and death of the oligo-
dendrocytes (1). Based in part on analogy with the disease
model experimental allergic encephalomyelitis (EAE), MS
is thought to be an autoimmune disorder mediated by au-
toaggressive T cells that recognize myelin antigens in the
context of class II HLA molecules (2). However, because
neither the putative antigens that trigger these autoimmune
responses nor the precise mechanisms responsible for de-
myelination in human MS have been unequivocally identi-
fied, the design of therapies that aim to prevent myelin de-
struction remains a challenge (2).
Nerve growth factor (NGF), a pleiotropic cytokine of the
neurotrophin family, promotes the biosynthesis of myelin
by oligodendrocytes in the CNS (3, 4) and by Schwann
cells in the peripheral nervous system (5). These myelin-
promoting effects of NGF appear to be mediated by the
high affinity NGF receptor TrkA rather than by the low af-
finity NGF receptor p75
 
NGFR
 
 (6, 7). In addition to its role
in myelination, neuronal growth, and CNS differentiation
(8), NGF is known to have pleiotropic effects on various
cells of the immune system (9). The immunomodulatory
properties of NGF, and its trophic effects on myelin-pro-
ducing cells, provide a framework for the use of NGF in
the treatment of immune-mediated demyelinating disor-
ders. Here, we report that therapy with recombinant human
(rh)NGF protects against CNS inflammation and demye-
lination in a nonhuman primate model of EAE, the com-
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mon marmoset 
 
Callithrix jacchus
 
. This antiinflammatory ef-
fect of NGF has not been previously reported, and appears
to be mediated by an alteration of the balance between
Th1 and Th2 cytokines within the CNS.
 
Materials and Methods
 
Animals and Treatment Groups. C
 
.
 
 jacchus
 
 marmosets were
maintained in a primate colony at the University of California,
San Francisco, and were cared for in accordance with all institu-
tional guidelines. Phlebotomy and cerebrospinal fluid (CSF) col-
lection were performed under anesthesia in accordance with
standard approved protocols. For intracerebroventricular admin-
istration of treatments, a sterile 36-gauge polycarbonate cannula
secured inside a stainless steel brain cannulation device (Alzet) was
stereotaxically implanted into the right lateral cerebral ventricle
under anesthesia with isoflurane (coordinates: AP 6 mm, L 1.25
mm, V 7 mm, relative to bregma [10]). The cannula was secured
to the skull with miniature bone screws and dental acrylic ce-
ment, and connected by a 28-gauge polyvinyl tubing tunneled
under the skin to an osmotic minipump (model 2004; Alzet) de-
livering 0.9% NaCl and implanted subcutaneously on the right
flank. 7–14 d after surgery, on the day when EAE was induced,
subcutaneous treatment minipumps containing either rhNGF or
cytochrome c (CYT) as a placebo (Boehringer) at a concentration
of 1 mg/ml were substituted. The minipumps delivered 6 
 
m
 
l/d,
and due to the dead volume of the tubing connecting the
minipump and the brain cannula, drugs were delivered beginning
7 d after immunizations and until completion of the experiments.
 
Induction and Assessment of EAE.
 
EAE was induced by active
immunization with 100 
 
m
 
g of a recombinant protein correspond-
ing to the extracellular domain of rat MOG (rMOG) in combi-
nation with CFA and 
 
Bordetella pertussis
 
 as described previously
(11). Clinical signs of EAE were recorded daily by an observer
blinded to the treatment groups using a grading scale specifically
developed for marmosets in our laboratory (Table I). 28 d after
immunization, animals were killed under deep phenobarbital an-
esthesia by intracardiac perfusion with PBS followed by either 4%
buffered paraformaldehyde or 3% paraformaldehyde/0.2% glu-
taraldehyde. Brain hemispheres, optic nerves, and spinal cord
were removed and dissected in 1-mm-thick consecutive blocks,
which were paraffin-embedded for routine histology and/or cry-
opreserved and stored at 
 
2
 
80
 
8
 
C for immunocytochemistry.
Pathological scores were assigned to paired sections throughout
the entire neuraxis, using a grading scale to quantitate inflamma-
tion and demyelination: 0, normal; 
 
1
 
, rare (1–3/section) perivas-
cular cuffs with minimal demyelination; 
 
11
 
, 3–10 perivascular
cuffs/section accompanied by moderate demyelination; 
 
111
 
,
widespread perivascular cuffing, extensive demyelination with
large confluent lesions.
 
Immunocytochemistry.
 
Sections of brain and spinal cord (5–30
 
m
 
m) were pretreated with 1% H
 
2
 
O
 
2
 
 in Tris-Cl buffer, and
blocked with 5% normal goat serum (Vector Laboratories) and
0.3% Triton X-100 for 60 min. Sections were incubated in se-
quence with the primary antibodies overnight at 4
 
8
 
C, an appro-
priate biotinylated secondary antibody, and avidin–horseradish
peroxidase complex (Vectastain ABC; Vector Laboratories), then
developed with 3, 3
 
o
 
-diamino-benzidine (Sigma-Aldrich) and
counterstained with hematoxylin (Research Genetics). The pri-
mary antibodies and their working dilutions were as follows: for
NGF receptors, rabbit anti–rat TrkA (RTA), 1:1,000; rabbit
anti–mouse p75
 
NGFR
 
 (Rex), 1:1,000 (both provided by Dr. Louis
Reichardt, University of California, San Francisco); rabbit anti–
human TrkA (Sc 118; Santa Cruz Biotechnology, Inc.), 1:1,000;
mouse anti–human p75
 
NGFR
 
 (Boehringer), 1:1,000; for cytokines,
mouse anti–monkey IFN-
 
g
 
 (MD1; U-Cytech), 1:50; and mouse
anti–human IL-10 (MCA B-S10; Instruchemie), 1:100. Slides
stained for IFN-
 
g
 
 and IL-10 were pretreated by overheating in a
microwave for retrieval of antigens. For each cytokine, four con-
secutive slides on two sections from each animal were stained,
which included an average of 12 
 
6 
 
10 (mean 
 
6 
 
SD) inflamma-
 
Table I.
 
Expanded Disability Status Scale for Marmoset EAE
 
Function Disability score
Maximal
score
1 Alertness 0: normal; 1: reduced; 2: lethargic 2
2 Spontaneous mobility 0: normal; 1: mild slowing; 2: marked slowing; 3: absent 3
3 Tremor 0: none; 1: moderate; 2: severe 2
4 Tone
 
*
 
0: normal; 1: mildly reduced; 2: markedly reduced; 3: absent 12
5 Motor (grip)
 
*
 
0: normal; 1: mildly reduced; 2: markedly reduced; 3: absent 12
6 Sensory
 
*
 
Light touch 0: normal; 1: reduced; 2: absent 8
Pain
 
‡
 
0: normal; 1: reduced; 2: absent 8
 
‡
 
7 Eye movements 0: normal; 1: abnormal 1
8 Vision (including pupillary reflex) 0: normal; 1: abnormal; 2: absent 2
9 Vocalization 0: normal; 1: changed 1
10 Bladder function 0: normal; 1: abnormal 1
11 Other signs 0: normal; 1: abnormal 1
The total score is derived by adding the scores for each system. The maximal score for the scale is 45.
 
*
 
Scored in each limb.
 
‡
 
Scored only if tactile not present.
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tory infiltrates per slide; quantitation of infiltrates and positively
stained cells was done using a grid of 250 
 
3 
 
250 
 
m
 
m.
 
Bioassay for rhNGF.
 
CSF levels of rhNGF were determined
using a specific bioassay of cell survival in primary cultures of
neural crest–derived chicken embryonic sensory neurons (12). In
brief, dorsal root ganglia neurons were extracted from embryos,
cultured in F14 medium with 10% horse serum and antibiotics,
and then seeded onto poly-ornithine/laminin–coated wells in
microtiter plates in the presence or absence of known concentra-
tions of rhNGF, or aliquots of CSF (10–50 
 
m
 
l). Neuronal survival
was assessed after 48 h by counting the number of surviving neu-
rons with neurite elongation under a phase–contrast microscope.
Neurotrophic activity was expressed as one half of the maximal
stimulation index (EC
 
50
 
), e.g., 100 pg/ml for rhNGF.
 
Assessment of Peripheral Immune Reactivity.
 
T cell proliferative
responses were performed using a standard 
 
3
 
H[thymidine] incor-
poration assay with 2 
 
3
 
 10
 
5
 
 freshly isolated marmoset or human
PBMCs (11) incubated with the following: no antigen; rMOG,
10 
 
m
 
g/ml; PHA, 2 
 
m
 
g/ml; killed 
 
Staphylococcus aureus
 
 Cowan
strain (SAC), 1:10,000; LPS, 20 ng/ml; or rhNGF, 100 ng/ml.
Stimulation indices were calculated as the ratio of 
 
3
 
H[thymidine]
incorporation in stimulated to unstimulated (medium alone)
wells. Serum antibody responses were tested by ELISA in 96-well
plates coated with 1 
 
m
 
g rMOG/well using 100 
 
m
 
l of serum dilu-
tions of 
 
C
 
.
 
 jacchus
 
 sera and 100 
 
m
 
l of peroxidase-conjugated anti–
monkey IgG (1:4,000; Sigma-Aldrich) (11). Plates were devel-
oped with 
 
o
 
-phenylenediamine-peroxidase substrate and read at
490 nm in a Vmax ELISA reader (Molecular Devices).
 
Flow Cytometry.
 
Staining for flow cytometry studies was per-
formed after blockade of Fc receptors with PBS plus 1% BSA and
10% goat serum (Vector Laboratories). Cells were stained with
the following antibodies and the appropriate isotype controls: 20
 
m
 
l unconjugated goat anti–human TrkA or mouse anti–human
p75
 
NGFR
 
 antibody followed by FITC-conjugated anti–goat or
anti–mouse IgG (Jackson ImmunoResearch Laboratories); double
staining was performed with PE-conjugated anti-CD4 (Beckman-
Coulter), CD20 (Immunotech), or CD14 (Beckman-Coulter).
Samples were analyzed in a Becton Dickinson FACScan™ appa-
ratus, and data analysis was done by subtracting isotype control
percentage from experimental percentage.
 
Statistical Analysis.
 
Clinical and histological scores in the
treatment groups were compared with the Mann-Whitney sum
rank test, using StatView II software (Abacus). Quantitative im-
munohistochemistry for IFN-
 
g
 
 and IL-10 was analyzed by the
Student’s 
 
t
 
 test. A
 
 P 
 
value 
 
# 
 
0.05 was considered significant. Re-
sults are expressed as mean 
 
6 
 
SD.
 
Results and Discussion
 
NGF Inhibits the Development of EAE in C. jacchus Marmo-
sets.
 
Beginning 7 d after induction of EAE, 
 
C
 
.
 
 jacchus
 
marmosets were randomly assigned to treatment with ei-
ther rhNGF or CYT as placebo administered via the in-
tracerebroventricular cannula. In this experimental design,
we chose to use an intracranial route to ensure accurate de-
livery of the drug into the CNS. This resulted in sustained
elevated concentrations of rhNGF in the CSF of all
rhNGF-treated animals (2–300 ng/ml), as measured by a
specific bioassay.
Consistent with previous experience in MOG-sensitized
marmosets (11), six placebo (CYT)-treated animals devel-
oped moderate to severe clinical signs of EAE beginning
 
10–16 d after immunization. Clinical signs in most of these
animals progressed by the end of the study (day 28 after im-
munization). By contrast, a total of six rhNGF-treated mar-
mosets showed either no clinical signs or a markedly atten-
uated disease course (Table II). In those rhNGF-treated
animals that developed clinical signs, the onset of EAE was
delayed compared with controls (day 21 
 
6 
 
0.9 vs. day 11 
 
6
 
0.4 after immunization,
 
 P 
 
5 
 
0.02). Maximal clinical scores
observed averaged 12.5 
 
6 
 
2.3 in controls vs. 2.6 
 
6 
 
0.9 in
rhNGF-treated animals (
 
P
 
 
 
5 
 
0.01).
Neuropathological evaluation confirmed the observed
clinical protection. Placebo-treated animals displayed typi-
cal large perivascular infiltrates comprised of mononuclear
cells and macrophages accompanied by extensive concen-
tric demyelination with gliosis widely distributed through-
out the CNS. In rhNGF-treated marmosets, the number
and size of the inflammatory infiltrates were reduced and
demyelination was minimal (Fig. 1, and Table III). Al-
though differences in severity and in the affected CNS re-
gions existed between individual marmosets, the disease
burden was greatly reduced in animals treated with rhNGF
compared with controls. In both treatment groups, the
amounts of demyelination and inflammation were concor-
dant. Thus, treatment with rhNGF inhibited the develop-
ment of inflammatory demyelination in marmosets.
Several considerations dictated the choice of the 
 
C
 
.
 
 jac-
chus
 
 model of EAE for this study. First, this nonhuman pri-
mate species is best suited to test the efficacy of the human
NGF protein, due to potential species-related differences in
the expression of the NGF receptors TrkA and p75
 
NGFR
 
Table II.
 
Clinical Findings in rhNGF- and Placebo-treated 
Animals
 
Onset of EAE
Animal Day pi Score
Maximal
clinical score (Day pi)
rhNGF group
26.30.92 28 2 2 (28)
26.29.94 14 3 6.5 (28)
UC5.95 20 3.5 4 (27)
101 19 2 2.5 (18)
231.90 – 0 0 (–)
FL 5.96 21 1 1 (21)
Placebo group
26.17.94 17 11 14 (17)
26.33.93 10 2 21 (28)
157.94 7 2 5 (19)
198.94 7 2 14.5 (28)
FL 3.95 15 1 7.5 (28)
FL 6.96 14 1 13 (19)
pi, post immunization.
 1802
 
Nerve Growth Factor as Therapy for Autoimmune Demyelination
 
(13). Second, pathological features of rMOG-induced EAE
in 
 
C
 
.
 
 jacchus
 
 include moderate CNS inflammation, an early
demyelinating component, and significant remyelination,
all characteristics found in human MS. Third, the mecha-
nisms of demyelination in 
 
C
 
.
 
 jacchus
 
 EAE and MS are simi-
lar and involve vesicular disruption of myelin mediated by
autoantibodies that recognize MOG (14). Treatment with
rhNGF was begun 7 d after immunization, presumably at a
stage of EAE where immune responses against the immu-
nizing antigen had already developed. We had hypothe-
sized that in this experimental design the effect of treat-
ment, if any, would be to promote clinical recovery and
remyelination in the rhNGF-treated animals. Surprisingly,
rhNGF prevented the initial development and delayed the
onset of clinical signs of EAE, and suppressed both the in-
flammatory and demyelinating components of CNS pa-
thology. Because most of the rhNGF-treated animals dis-
played only minimal demyelination, it was not possible to
assess differences in remyelination.
Based on in vitro observations in rodents, several growth
factors with trophic and survival effects on oligodendro-
cytes have been considered for therapy in demyelinating
disorders, including insulin-like growth factor (IGF)-1,
glial growth factor (GGF)-2, platelet-derived growth fac-
tor, ciliary neurotrophic factor, and fibroblast growth factor
(15). In vivo, both IGF-1 and GGF-2 (15, 16) have been
shown to be capable of reducing disease severity in murine
EAE; however, exacerbation of disease has also been de-
scribed with IGF-1 (17). It is important to recognize that,
due to the interspecies differences in the biological effects
of growth factors and the differential expression of their
specific receptors, information derived from rodent studies
may not be applicable to humans. Our study clearly dem-
onstrates that NGF protects against CNS inflammatory and
Figure 1. Representative neuropathological
findings in placebo- (A) and rhNGF-treated (B)
animals at the completion of the study (day 28 after
immunization). Gross anatomical views of coronal
sections through the temporal lobe illustrate multi-
ple demyelinating plaques disseminated through-
out the subcortical white matter in the control. In
the rhNGF-treated animal, the density of plaques
is markedly reduced. The paraffin-embedded sec-
tions were stained with Luxol Fast blue/periodic
acid-Schiff.
 
Table III.
 
Neuropathological Findings
 
CNS region
Animal
Subcortical
white matter
Corpus
callosum
Optic chiasm,
nerves, and tracts
Brain stem,
cerebellum
Cervical
spinal cord
Thoracic
spinal cord
Lumbar
spinal cord
rhNGF group
26.30.92
 
11 1 11
 
0–
 
1 1 1
 
0
26.29.94
 
1
 
0–
 
1
 
0–
 
1
 
0 0 0–
 
1
 
0–
 
1
 
UC5.95 0 1 0 0 1 0 0
101 0 0 0 0 1 0 0
231.90 1 0 1 1 1 1 1
FL 5.96 1 11 1 0 0 0 0
Placebo group
26.17.94 111 11 111 11 111 111 11
26.33.93 1–11 1–11 111 1–11 111 111 11–111
157.94 0 0 111 0 11 0 0
198.94 1 0 1 0 111 11–111 11
FL 3.95 0 1 11 1 11 0 0
FL 6.96 0 1 0 0 11 0 0
Paired CNS sections were scored using a combined scale for inflammation and demyelination (0 to 111; see Materials and Methods).
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demyelinating disease in a nonhuman primate species that
is known to develop EAE lesions that are indistinguishable
from acute lesions of MS (14). Although NGF has been
shown to ameliorate experimental allergic neuritis (18), to
our knowledge this growth factor has not been tested in
rodent EAE and it is possible that its protective effect is re-
stricted to primate species.
Mechanisms Responsible for the Protective Effects of NGF.
Expression of NGF receptors in the CNS of marmosets
was studied by immunocytochemistry, using antibodies
against human or rat surface antigens. Both the high affin-
ity NGF receptor (TrkA) and the low affinity NGF recep-
tor (p75NGFR) were detected in marmoset basal forebrain
neurons, indicating that these antibodies fully cross-reacted
with C. jacchus NGF receptors (Fig. 2 A). In CNS white
matter, widespread expression of TrkA and p75NGFR was
detected in cells that had the morphologic appearance of
astrocytes and/or microglial cells (Fig. 2 B) and in oligo-
dendrocytes (not shown). In addition, a proportion of the
mononuclear cells and macrophages comprising the in-
flammatory infiltrates of EAE lesions were positive for
TrkA and p75NGFR (Fig. 2 C). Expression of NGF recep-
tors on marmoset immune cell subsets was studied by
FACS® analysis, using double staining of PBMCs. Both
the TrkA receptor and the p75NGFR were widely expressed
in CD41 T cells (52 and 67%, respectively), monocytes
(57 and 56%), and in a small subpopulation of B cells (6
and 9%) (data not shown). Thus, in this nonhuman pri-
mate system, glial and inflammatory cells within the CNS
and a large proportion of immune cells in the periphery
expressed NGF receptors, raising the possibility that several
regulatory pathways may have participated in the protec-
tive effect of NGF on EAE.
To assess whether treatment with rhNGF modified the
response of the peripheral immune system to the immu-
nizing antigen, MOG-induced proliferative responses in
PBMCs and serum anti-MOG antibody titers were moni-
tored at days 0, 14, and 28 of the study. MOG-specific
proliferative responses and anti-MOG antibody titers were
similar in rhNGF- and placebo-treated animals (Fig. 3), in-
dicating that peripheral T cell and B cell responses were
not affected by intracerebral administration of NGF. Addi-
tional experiments using PBMCs and macrophages isolated
from normal subjects and stimulated with PHA, SAC, or
LPS in the presence or absence of exogenous rhNGF (1–
1,000 ng/ml) confirmed that rhNGF did not interfere with
either proliferative responses or macrophage reactivity.
Finally, the expression of NGF receptors on subsets of
Figure 2. Characterization of NGF re-
ceptors in marmoset brain by immunohis-
tochemistry. Staining for TrkA is shown at
the left (5-mm paraffin-embedded section),
and for p75NGFR at the right (30-mm-thick
section stained in flotation). (A) Both NGF
receptors are present in cholinergic neurons
of the basal forebrain. Arrows show satellite
oligodendrocytes stained for TrkA (left). (B)
Arrows indicate some of the TrkA- and
p75NGFR-positive glial cells (astrocytes or
microglia) in normal white matter. (C) In
CNS inflammatory infiltrates, strong staining
for both NGF receptors is also apparent on
many mononuclear cells and macrophages
(arrows). Original magnifications: 3400.
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PBMCs was not modified by preincubation with exogenous
rhNGF at concentrations ranging from 1 to 1,000 ng/ml
(data not shown). Taken together, these data suggest that
treatment with NGF inhibited the development of EAE
through interference with effector mechanisms of EAE pa-
thology rather than through modulation of the induction
phase of EAE.
Cytokines produced by T cells may profoundly influence
the course of autoimmune disorders (19). In rodents and in
marmosets, CNS inflammation results from the priming of
Th1 cells that secrete proinflammatory cytokines such as
TNF-a and IFN-g. Conversely, EAE can be inhibited by
immunosuppressive cytokines (IL-4, IL-5, IL-10, and
TGF-b) produced by Th2 cells (for a review, see reference
2). In the current study, we examined the expression of
IFN-g and IL-10 within the CNS of placebo- and NGF-
treated marmosets by immunocytochemistry. Results are
presented in Fig. 4 and Table IV. In agreement with the
scores of standard histological analysis, placebo-treated con-
trols had significantly more infiltrates than rhNGF-treated
animals (20.2 6 9.0 vs. 7.3 6 8.0, respectively). Consistent
with a Th1 response, IFN-g was expressed at high levels by
infiltrating inflammatory cells in these controls. In marked
contrast, IFN-g was mostly absent from perivascular in-
flammatory cuffs in rhNGF-treated marmosets (Fig. 4, A
and B). An opposite pattern was seen for the expression of
IL-10, which was markedly upregulated in inflammatory
infiltrates of rhNGF-treated animals compared with con-
trols. Quantitative analysis confirmed that these differences
between the two treatment groups were significant, with
the exception of the absolute number of IL-10–positive
inflammatory cells per infiltrate (Table IV). This was be-
cause IL-10 was expressed in lesions from controls, which
included more inflammatory cells than infiltrates from
rhNGF-treated animals. However, the percentage of IL-
10–positive cells per infiltrate was increased in rhNGF-
treated marmosets (Table IV). In addition to inflammatory
lesions, IL-10 was distinctly expressed at high levels in glial
cells of normal-appearing white matter in NGF-protected
marmosets. These cells had the morphology of astrocytes,
although activated microglia cannot be formally excluded,
Figure 3. Serial measure-
ments of T cell and antibody re-
activity against MOG during the
course of EAE in placebo- and
rhNGF-treated marmosets. (A)
MOG-specific T cell proliferative
responses in marmoset PBMCs
at days 0, 14, and 28 after immu-
nization. (B) Serum anti-MOG
antibody titers measured by
ELISA at day 28 after immuniza-
tion. The differences between
placebo- and rhNGF-treated an-
imals were not statistically signif-
icant.
Figure 4. Effects of rhNGF on cytokine
production within the CNS of nonhuman
primates. Representative sections from pla-
cebo-treated (left) and rhNGF-treated
(right) marmosets. (A and B) Staining for
IFN-g demonstrates the presence of this cy-
tokine in inflammatory mononuclear cells
in the center of a perivascular infiltrate from
a placebo-treated animal (some designated
by arrows); complete suppression is evident
in an infiltrate from an rhNGF-treated ani-
mal. (C and D) Staining for IL-10, demon-
strating strong upregulation of this cytokine
in astrocytes of the corpus callosum (normal
white matter) in an rhNGF-treated animal.
Original magnifications: 3400.
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and did not express IFN-g (Fig. 4, C and D; Table IV).
Taken together, these results indicate that the protective ef-
fect of NGF was mediated through local modulation of the
intracerebral network of cytokines produced by inflamma-
tory cells of the perivascular infiltrates, and by glial cells in
the unaffected CNS white matter.
The production of NGF is increased in a variety of CNS
disorders, including brain injury (20), acute rodent EAE
(21), and during the relapsing phase of MS (22). These
conditions are associated with the presence of cytokines
that stimulate the production of NGF by astrocytes, such as
IL-1, TNF-a (23), IL-4, and IL-5 (24), which perhaps rep-
resents a physiological response to tissue injury (25). Our
observation that NGF in turn can modulate cytokine ex-
pression by inflammatory and glial cells in EAE underlines
the importance of this molecule as a potent autocrine, anti-
inflammatory cytokine produced within the blood–brain
barrier. The effect of NGF on IL-10 expression appears
similar to that reported for the neuroregulin GGF-2 (16),
and may be a common immunomodulatory pathway for
several CNS growth factors. In diseases like EAE and MS,
presentation of myelin antigens to T cells is dependent on
the expression of class II HLA molecules on astrocytes and
macrophages/microglia, which is upregulated by IFN-g
(26) and downregulated by IL-10 (27). Thus, a possible ef-
fector mechanism for the protective action of NGF could
be decreased HLA class II expression within the CNS, ei-
ther indirectly through its effects on IFN-g and IL-10 pro-
duction or by a direct effect on astrocytes (28). Indeed, fur-
ther investigations are needed in this primate system with
close phylogenetic similarity to humans, to determine
whether the effects of NGF on CNS cytokine production
provide long-term benefit in a chronic experimental de-
sign. In light of recent evidence suggesting a role for neu-
ronal damage as a mechanism participating in the patho-
genesis of MS lesions (29, 30), NGF or agonist compounds
could represent a novel therapeutic alternative for demye-
linating disorders that combines the benefits of neuropro-
tection and modulation of CNS autoimmunity.
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